Natera (NASDAQ:NTRA) Hits New 52-Week High on Analyst Upgrade

Share on StockTwits

Shares of Natera Inc (NASDAQ:NTRA) reached a new 52-week high on Monday after Cowen raised their price target on the stock from $30.00 to $42.00. Cowen currently has an average rating on the stock. Natera traded as high as $40.92 and last traded at $40.05, with a volume of 35352 shares traded. The stock had previously closed at $38.51.

A number of other analysts have also weighed in on NTRA. Zacks Investment Research upgraded shares of Natera from a “sell” rating to a “hold” rating in a research note on Friday, August 9th. ValuEngine lowered shares of Natera from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Craig Hallum upped their target price on shares of Natera from $29.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. Piper Jaffray Companies set a $45.00 target price on shares of Natera and gave the stock a “buy” rating in a research note on Friday, October 11th. Finally, BidaskClub upgraded shares of Natera from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, October 8th. Three equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. Natera presently has a consensus rating of “Buy” and a consensus target price of $38.40.

In related news, CFO Michael Burkes Brophy sold 43,954 shares of Natera stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $29.00, for a total transaction of $1,274,666.00. Following the sale, the chief financial officer now directly owns 26,690 shares in the company, valued at approximately $774,010. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Robert Alan Schueren sold 12,545 shares of Natera stock in a transaction on Friday, September 20th. The stock was sold at an average price of $33.19, for a total transaction of $416,368.55. Following the sale, the chief operating officer now owns 25,000 shares in the company, valued at $829,750. The disclosure for this sale can be found here. Insiders sold 438,947 shares of company stock valued at $13,888,596 over the last ninety days. 9.29% of the stock is currently owned by corporate insiders.

Large investors have recently made changes to their positions in the stock. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Natera by 23.3% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,837 shares of the medical research company’s stock worth $93,000 after acquiring an additional 537 shares in the last quarter. Focused Wealth Management Inc acquired a new stake in Natera during the 2nd quarter worth $83,000. US Bancorp DE raised its stake in Natera by 575.2% during the 2nd quarter. US Bancorp DE now owns 3,099 shares of the medical research company’s stock worth $86,000 after acquiring an additional 2,640 shares in the last quarter. Bank of Montreal Can purchased a new position in Natera during the 2nd quarter worth $129,000. Finally, United Services Automobile Association purchased a new position in Natera during the 2nd quarter worth $242,000. Hedge funds and other institutional investors own 94.95% of the company’s stock.

The company has a debt-to-equity ratio of 1.10, a quick ratio of 2.42 and a current ratio of 2.54. The company has a market capitalization of $2.70 billion, a PE ratio of -17.47 and a beta of 1.42. The company’s 50-day simple moving average is $34.39 and its 200-day simple moving average is $27.13.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Wednesday, August 7th. The medical research company reported ($0.48) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.57) by $0.09. Natera had a negative net margin of 46.78% and a negative return on equity of 273.92%. The company had revenue of $74.36 million for the quarter, compared to the consensus estimate of $66.77 million. During the same period last year, the firm posted ($0.62) EPS. Natera’s revenue for the quarter was up 17.9% on a year-over-year basis. Analysts expect that Natera Inc will post -2.1 EPS for the current year.

Natera Company Profile (NASDAQ:NTRA)

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Read More: Different Options Trading Strategies

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

FLIP Price Reaches $0.0109 on Top Exchanges
FLIP Price Reaches $0.0109 on Top Exchanges
Bristol-Myers Squibb Co  Given Consensus Rating of “Buy” by Brokerages
Bristol-Myers Squibb Co Given Consensus Rating of “Buy” by Brokerages
Coca Cola HBC AG  Given Consensus Rating of “Buy” by Analysts
Coca Cola HBC AG Given Consensus Rating of “Buy” by Analysts
Energy Recovery  Lowered to “Sell” at BidaskClub
Energy Recovery Lowered to “Sell” at BidaskClub
British Land  Given “Hold” Rating at Peel Hunt
British Land Given “Hold” Rating at Peel Hunt
Mondi  Given “Buy” Rating at UBS Group
Mondi Given “Buy” Rating at UBS Group


© 2006-2019 Ticker Report